Studies of platelet activating factor (PAF) antagonists from microbial products. II. Pharmacological studies of FR-49175 in animal models.

Abstract
Platelet activating factor (PAF) antagonistic action of FR-49175 was studied using in vivo models designated as PAF-induced bronchoconstriction, hypotension and vascular permeability increase. This compound (0.1 mg/kg, i.v.) significantly inhibited PAF-induced bronchoconstriction in guinea-pigs. However, it did not prevent PAF-induced hypotension in rats or vascular permeability increase in mice. Furthermore, the effect of this compound against a systemic anaphylaxis model in guinea-pigs was examined, but it did not show any inhibition of antigen-induced mortality at the dose of 10 mg/kg, i.v.

This publication has 1 reference indexed in Scilit: